We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

22 hedge funds and large institutions have $43.7M invested in Tonix Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

22% more funds holding

Funds holding: 18 → 22 (+4)

0% more ownership

Funds ownership: 0% → 0% (+0%)

15% less capital invested

Capital invested by funds: $51.2M → $43.7M (-$7.5M)

Holders
22
Holders Change
+4
Holders Change %
+22.22%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$6.04M
2
Prudential Financial
Prudential Financial
New Jersey
+$3.18M
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.54M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$1.91M
5
BlackRock
BlackRock
New York
+$1.59M

Top Sellers

Rank Fund Capital Flow
1
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$325K
2
Citadel Advisors
Citadel Advisors
Florida
-$318K
3
Deutsche Bank
Deutsche Bank
Germany
-$318K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$318K
5
VF
Virtu Financial
New York
-$318K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$11M +$1.59M +5 +12%
Vanguard Group
2
Vanguard Group
Pennsylvania
$7.02M +$1.91M +6 +24%
D.E. Shaw & Co
3
D.E. Shaw & Co
New York
$6.68M +$6.04M +19 +190%
Renaissance Technologies
4
Renaissance Technologies
New York
$3.83M +$2.54M +8 +89%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$2.58M -$318K -1 -8%
Prudential Financial
6
Prudential Financial
New Jersey
$2.48M +$3.18M +10 +1,000%
State Street
7
State Street
Massachusetts
$2.39M – – –
Northern Trust
8
Northern Trust
Illinois
$1.38M +$318K +1 +20%
N
9
Nuveen
North Carolina
$665K – – –
GCP
10
GSA Capital Partners
United Kingdom
$637K +$636K +2 +200%
Bank of America
11
Bank of America
North Carolina
$582K +$954K +3 New
Bank of New York Mellon
12
Bank of New York Mellon
New York
$399K – – –
Charles Schwab
13
Charles Schwab
California
$390K +$318K +1 +100%
AQR Capital Management
14
AQR Capital Management
Connecticut
$366K +$636K +2 New
Morgan Stanley
15
Morgan Stanley
New York
$313K +$318K +1 New
AFM
16
Anson Funds Management
Texas
$309K +$318K +1 New
Two Sigma Advisers
17
Two Sigma Advisers
New York
$307K +$318K +1 New
Goldman Sachs
18
Goldman Sachs
New York
$219K – – –
AA
19
ALPS Advisors
Colorado
$196K +$318K +1 New
RhumbLine Advisers
20
RhumbLine Advisers
Massachusetts
$129K – – –
PHK
21
Point72 Hong Kong
Hong Kong
$125K +$318K +1 New
UBS Group
22
UBS Group
Switzerland
$121K +$318K +1 New
Jane Street
23
Jane Street
New York
$111K – – –
VF
24
Virtu Financial
New York
$110K -$318K -1 Closed
Deutsche Bank
25
Deutsche Bank
Germany
$96K -$318K -1 Closed
1
2 3 4

TNXP Hedge Fund Activity: Q4 2021 in Review

22 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q4 2021, worth a combined $43.7M — down 15% from $51.2M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TNXP positions and 4 closed out — a net gain of 4 holders — while 8 added to existing stakes and 1 trimmed.

The largest buyer was D.E. Shaw & Co, adding an estimated $6.04M. The largest seller was Qube Research & Technologies (QRT), exiting entirely with an estimated $325K sold.

  • 22 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q4 2021, up from 18 in Q3 2021.
  • Funds reported $43.7M of Tonix Pharmaceuticals stock for Q4 2021, down 15% quarter-over-quarter.
  • 8 funds opened new Tonix Pharmaceuticals positions in Q4 2021 and 4 closed out, a net change of +4 holders.
  • The largest Tonix Pharmaceuticals buyer in Q4 2021 was D.E. Shaw & Co, an estimated $6.04M added.
  • The largest Tonix Pharmaceuticals seller in Q4 2021 was Qube Research & Technologies (QRT), an estimated $325K sold.

Based on aggregated 13F filings for Q4 2021.